TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE CLINICAL LABORATORY SERVICES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING INFECTIOUS DISEASES WORLDWIDE
3.1.2 ADVANCEMENT IN CLINICAL DIAGNOSTIC METHODS
3.1.3 DEVELOPMENT IN DATABASE MANAGEMENT TOOLS AND WIDE ACCEPTANCE OF POINT-OF-CARE (POC) TESTING SOLUTIONS
3.1.4 RISING DEMAND FOR EARLY AND ACCURATE DISEASE DIAGNOSIS
3.1.5 GROWING APPLICATION OF HIGH-THROUGHPUT ASSAYS
3.2 RESTRAINTS
3.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
3.2.2 STRICT REGULATORY POLICIES
3.3 OPPORTUNITIES
3.3.1 GROWING ADOPTION OF DIGITAL PATHOLOGY PLATFORMS
3.3.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
3.3.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE
3.3.4 STRATEGIC INITIATIVES BY MARKET PLAYERS
3.4 CHALLENGES
3.4.1 INACCURATE RESULTS OF TESTS
3.4.2 INADEQUATE REIMBURSEMENTS POLICIES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EUROPE CLINICAL LABORATORY SERVICES MARKET, BY SPECIALTY
6.1 OVERVIEW
6.2 CLINICAL CHEMISTRY TESTING
6.2.1 ROUTINE CHEMISTRY TESTING
6.2.2 THERAPEUTIC DRUG MONITORING (TDM) TESTING
6.2.3 ENDOCRINOLOGY CHEMISTRY TESTING
6.2.4 SPECIALIZED CHEMISTRY TESTING
6.2.5 OTHER CLINICAL CHEMISTRY TESTING
6.3 HEMATOLOGY TESTING
6.3.1 ROUTINE HEMATOLOGY TESTING
6.3.2 SPECIALIZED HEMATOLOGY TESTING
6.3.3 COAGULATION TESTING
6.4 MICROBIOLOGY TESTING
6.4.1 INFECTIOUS DISEASE TESTING
6.4.2 TRANSPLANT DIAGNOSTIC TESTING
6.4.3 OTHER MICROBIOLOGY TESTING
6.5 IMMUNOLOGY TESTING
6.6 DRUGS OF ABUSE TESTING
6.7 CYTOLOGY TESTING
6.8 GENETIC TESTING
7 EUROPE CLINICAL LABORATORY SERVICES MARKET, BY PROVIDER
7.1 OVERVIEW
7.2 HOSPITAL-BASED LABORATORIES
7.3 INDEPENDENT & REFERENCE LABORATORIES
7.4 NURSING AND PHYSICIAN OFFICE-BASED LABORATORIES
8 EUROPE CLINICAL LABORATORY SERVICES MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 BIOANALYTICAL & LAB CHEMISTRY SERVICES
8.3 DRUG DEVELOPMENT RELATED SERVICES
8.4 DRUG DISCOVERY RELATED SERVICES
8.5 TOXICOLOGY TESTING SERVICES
8.6 CELL & GENE THERAPY RELATED SERVICES
8.7 PRECLINICAL & CLINICAL TRIAL RELATED SERVICES
8.8 OTHER CLINICAL LABORATORY SERVICES
9 CLINICAL LABORATORY SERVICES MARKET, BY GEOGRAPHY
9.1 EUROPE
9.1.1 GERMANY
9.1.2 U.K.
9.1.3 ITALY
9.1.4 FRANCE
9.1.5 SPAIN
9.1.6 RUSSIA
9.1.7 NETHERLANDS
9.1.8 SWITZERLAND
9.1.9 BELGIUM
9.1.10 TURKEY
9.1.11 REST OF EUROPE
10 EUROPE CLINICAL LABORATORY SERVICES MARKET, COMPANY LANDSCAPE
10.1 COMPANY SHARE ANALYSIS: EUROPE
11 COMPANY PROFILE
11.1 SIEMENS HEALTHINEERS AG
11.1.1 COMPANY SNAPSHOT
11.1.1 REVENUE ANALYSIS
11.1.2 COMPANY SHARE ANALYSIS
11.1.3 SERVICE PORTFOLIO
11.1.4 RECENT DEVELOPMENT
11.2 SPECTRA LABORATORIES (A SUBSIDIARY OF FRESENIUS MEDICAL CARE AG & CO. KGAA)
11.2.1 COMPANY SNAPSHOT
11.2.2 REVENUE ANALYSIS
11.2.3 COMPANY SHARE ANALYSIS
11.2.4 SERVICE PORTFOLIO
11.2.5 RECENT DEVELOPMENT
11.3 DAVITA INC.
11.3.1 COMPANY SNAPSHOT
11.3.2 REVENUE ANALYSIS
11.3.3 COMPANY SHARE ANALYSIS
11.3.4 SERVICE PORTFOLIO
11.3.5 RECENT DEVELOPMENT
11.4 LABORATORY CORPORATION OF AMERICA
11.4.1 COMPANY SNAPSHOT
11.4.2 REVENUE ANALYSIS
11.4.3 COMPANY SHARE ANALYSIS
11.4.4 SERVICE PORTFOLIO
11.4.5 RECENT DEVELOPMENT
11.5 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
11.5.1 COMPANY SNAPSHOT
11.5.2 SERVICE PORTFOLIO
11.5.3 RECENT DEVELOPMENT
11.6 QUEST DIAGNOSTICS INCORPORATED
11.6.1 COMPANY SNAPSHOT
11.6.2 REVENUE ANALYSIS
11.6.3 COMPANY SHARE ANALYSIS
11.6.4 SERVICE PORTFOLIO
11.6.5 RECENT DEVELOPMENTS
11.7 SONIC HEALTHCARE
11.7.1 COMPANY SNAPSHOT
11.7.2 REVENUE ANALYSIS
11.7.3 SERVICE PORTFOLIO
11.7.4 RECENT DEVELOPMENTS
11.8 SYNLAB INTERNATIONAL GMBH
11.8.1 COMPANY SNAPSHOT
11.8.2 SERVICE PORTFOLIO
11.8.3 RECENT DEVELOPMENTS
11.9 ABBOTT
11.9.1 COMPANY SNAPSHOT
11.9.2 REVENUE ANALYSIS
11.9.3 PRODUCT PORTFOLIO
11.9.4 RECENT DEVELOPMENT
11.10 CHARLES RIVER
11.10.1 COMPANY SNAPSHOT
11.10.2 REVENUE ANALYSIS
11.10.3 SERVICE PORTFOLIO
11.10.4 RECENT DEVELOPMENT
11.11 KINGMED DIAGNOSTICS
11.11.1 COMPANY SNAPSHOT
11.11.2 SERVICE PORTFOLIO
11.11.3 RECENT DEVELOPMENTS
?
11.12 ACM EUROPE LABORATORIES
11.12.1 COMPANY SNAPSHOT
11.12.2 SERVICE PORTFOLIO
11.12.3 RECENT DEVELOPMENTS
11.13 AMEDES HOLDING GMBH
11.13.1 COMPANY SNAPSHOT
11.13.2 SERVICE PORTFOLIO
11.13.3 RECENT DEVELOPMENT
11.14 BIOREFERENCE LABORATORIES, INC. (A SUBSIDIARY OF OPKO HEALTH, INC.)
11.14.1 COMPANY SNAPSHOT
11.14.2 REVENUE ANALYSIS
11.14.3 SERVICE PORTFOLIO
11.14.4 RECENT DEVELOPMENT
11.15 EUROFINS SCIENTIFIC
11.15.1 COMPANY SNAPSHOT
11.15.2 REVENUE ANALYSIS
11.15.3 SERVICE PORTFOLIO
11.15.4 RECENT DEVELOPMENT
11.16 GENOMIC HEALTH
11.16.1 COMPANY SNAPSHOT
11.16.2 REVENUE ANALYSIS
11.16.3 PRODUCT PORTFOLIO
11.16.4 RECENT DEVELOPMENT
11.17 LIFELABS
11.17.1 COMPANY SNAPSHOT
11.17.2 SERVICE PORTFOLIO
11.17.3 RECENT DEVELOPMENTS
11.18 MIRACA HOLDINGS INC.
11.18.1 COMPANY SNAPSHOT
11.18.2 REVENUE ANALYSIS
11.18.3 SERVICE PORTFOLIO
11.18.4 RECENT DEVELOPMENT
11.19 NEOGENOMICS LABORATORIES, INC
11.19.1 COMPANY SNAPSHOT
11.19.2 REVENUE ANALYSIS
11.19.3 SERVICE PORTFOLIO
11.19.4 RECENT DEVELOPMENTS
?
11.20 UNILABS
11.20.1 COMPANY SNAPSHOT
11.20.2 SERVICE PORTFOLIO
11.20.3 RECENT DEVELOPMENTS
12 QUESTIONNAIRE
13 RELATED REPORTS